**SUPPLEMENTARY FIGURE**

**Supplementary Figure 1. Additional performance characteristics of the AMK test.**

**(A)** Receiver-Operating Characteristic Curve for the multi-center, prospective study for AlloMap Kidney focusing on ABMR or mixed rejections (*n* = 86, 21 ABMR or mixed rejections; 65 non-rejections). AlloMap Kidney accurately differentiated ABMR or mixed rejections from non-rejections with ROC AUC of 0.79 (95% Confidence Interval (CI): 0.69-0.89). **(B)** Receiver-Operating Characteristic Curve for the multi-center, prospective study for AlloMap Kidney focusing on TCMRs (*n* = 81, 16 TCMR rejections; 65 non-rejections). AlloMap Kidney accurately differentiated TCMR rejections from non-rejections with ROC AUC of 0.75 (95% CI: 0.61-0.90). **(C)** Performance of the AMK test across GEP scores. PPV\_10 indicates Positive Predictive Value at 10% prevalence of rejection; NPV\_10 indicates Negative Predictive Value at 10% prevalence of rejection; PPV\_15 indicates Positive Predictive Value at 15% prevalence of rejection; NPV\_15 indicates Negative Predictive Value at 15% prevalence of rejection; PPV\_25 indicates Positive Predictive Value at 25% prevalence of rejection; NPV\_25 indicates Negative Predictive Value at 25% prevalence of rejection. NC = not computable. **(D)** Performance of the AMK test across AlloMap Kidney scores. NPV\_10, NPV\_15 and NPV\_25 indicates Negative Predictive Value at 10%, 15% and 25% prevalence of rejection, respectively (*n* = 235, 66 rejections, 169 non-rejection or quiescence specimens).

